Eloralintide vs Tirzepatide
A selective, long-acting amylin agonist that reaches GLP-1-class weight loss without touching the GLP-1 receptor. A dual GIP and GLP-1 receptor agonist — the first of the co-agonists. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Eloralintide | Tirzepatide | |
|---|---|---|
| Also known as | — | Mounjaro, Zepbound |
| Type | Analog | Analog |
| Evidence | Investigational | Established |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | Selective long-acting amylin analog (acylated 37 aa peptide) | Dual GIP/GLP-1 receptor agonist (39 aa, acylated) |
| Receptor / target | Amylin receptors (calcitonin receptor + RAMP), AMY1-selective | GIP receptor + GLP-1 receptor |
| Molecular weight | ~4,526 Da | ~4,813.5 Da |
| Half-life | ||
| Based on | Amylin | Glucose-dependent insulinotropic polypeptide |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Eloralintide and Tirzepatide?
- Eloralintide is an engineered analog based on Amylin; Tirzepatide is an engineered analog based on Glucose-dependent insulinotropic polypeptide. Eloralintide signals at Amylin receptors (calcitonin receptor + RAMP), AMY1-selective; Tirzepatide signals at GIP receptor + GLP-1 receptor.
- How do the half-lives of Eloralintide and Tirzepatide compare?
- The reported circulating half-life of Eloralintide is ~13–15 days (310–366 h); Tirzepatide is ~5 days (~120 h). These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? Tirzepatide vs Eloralintide. Or open the interactive comparison tool to add more molecules.